Perthera is the market and technology leader in developing Precision Cancer Analysis ('PCA') used to provide detailed full molecular information about cancer tumors. The PCA is a first step in the use of 'precision' (sometimes called 'personalized') medical treatments for cancer patients. It is based in the Tysons Corner area of Northern Virginia.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/30/16 | $8,700,000 | Series A |
Pilot Growth Equity | undisclosed |
